

**Table 1.** Baseline characteristics of patients with biopsy-proven NAFLD, stratified by sex and SVR tertiles.

	Men				Women			
	T1	T2	T3	<i>P</i> value	T1	T2	T3	<i>P</i> value
<i>N</i>	148	148	147		57	57	56	
<b>Demographics</b>								
Age (years)	42 ± 12	40 ± 11	35 ± 9*	<0.001	56 ± 10	49 ± 11 <sup>§</sup>	45 ± 10 <sup>§</sup>	<0.001
<b>Anthropometry</b>								
Diastolic BP (mmHg)	83 ± 11	82 ± 11	80 ± 10*	0.044	81 ± 10	83 ± 12	82 ± 10	0.728
Systolic BP (mmHg)	129 ± 14	127 ± 15	126 ± 15*	0.034	132 ± 17	130 ± 17	127 ± 18	0.331
SVR (g/mm <sup>2</sup> )	1.9 ± 0.2	2.4 ± 0.1	3.3 ± 0.6	<0.001	1.2 ± 0.3	1.7 ± 0.1	2.3 ± 0.4	<0.001
<b>Concomitant diseases</b>								
Type 2 diabetes, n (%)	35 (23.6)	33 (22.3)	19 (12.9)*	0.044	26 (45.6)	20 (35.1)	17 (29.8)	0.229
Hypertension, n (%)	32 (21.6)	24 (16.2)	19 (12.9)	0.133	31 (54.4)	20 (35.1)	14 (24.6) <sup>§</sup>	0.005
Overweight/obesity, n (%)	138 (93.2)	125 (84.5)	107 (72.3)*	<0.001	42 (73.7)	46 (80.7) <sup>§</sup>	33 (57.9)	0.034
<b>Clinical characteristics</b>								
Total bilirubin (μmol/L)	14.8 ± 7.2	15.3 ± 7.9	14.7 ± 6.5	0.739	11.2 ± 3.9	11.2 ± 4.6	12.1 ± 5.1	0.489
Albumin (g/L)	47 (44, 18)	47 (45, 50)	47 (45, 49)	0.162	44 (40, 46)	45 (43, 47)	45 (43, 48) <sup>§</sup>	0.027
Platelet count (×10 <sup>9</sup> )	241 ± 62	233 ± 52	252 ± 60*	0.014	239 ± 65	269 ± 67	253 ± 72	0.062
AST (U/L)	36 (26, 57)	33 (25, 54)	33 (25, 51)	0.253	33 (25, 54)	35 (24, 56)	36 (24, 49)	0.960
ALT (U/L)	62 (38, 107)	52 (33, 97)	58 (31, 100)	0.225	38 (22, 68)	40 (25, 69)	40 (22, 74)	0.756
ALP (U/L)	79 (68, 97)	83 (69, 98)	79 (67, 95)	0.439	95 (77, 109)	79 (69, 106)	84 (54, 102)	0.070
GGT (U/L)	59 (41, 97)	59 (37, 86)	55 (34, 85)	0.251	38 (24, 70)	40 (25, 83)	39 (23, 60)	0.945
Fasting glucose (mmol/L)	5.4 (4.9, 6.2)	5.2 (4.8, 6.0)	5.2 (4.9, 5.7)	0.139	6.1 (5.2, 7.9)	6 (5.1, 7.4)	5.2 (4.9, 6.6)	0.059
Uric acid (mmol/L)	431 ± 107	413 ± 102	415 ± 88	0.243	315 ± 85	328 ± 86	326 ± 76	0.667

Total cholesterol (mmol/L)	5.4 ± 1.3	5.2 ± 1.1	5.1 ± 1.1	0.080	4.9 ± 1.2	5.4 ± 1.0 <sup>§</sup>	5.1 ± 1.2	<b>0.039</b>
Triglycerides (mmol/L)	2.1 (1.6, 3.1)	2.1 (1.5, 3.0)	1.9 (1.3, 2.9)	0.150	1.6 (1.2, 2.3)	1.8 (1.3, 2.9)	1.8 (1.3, 2.4)	0.393
HDL-C (mmol/L)	0.97 ± 0.19	0.97 ± 0.19	0.99 ± 0.21	0.587	1.1 ± 0.3	1.1 ± 0.2	1.1 ± 0.2	0.635
LDL-C (mmol/L)	3.2 ± 1.0	3.0 ± 0.8	3.0 ± 0.9	0.096	2.7 ± 0.8	3.0 ± 0.8	2.9 ± 0.9	0.147
<b>Liver histology, n (%)</b>								
<b>Steatosis</b>				0.111				0.257
1	51 (34.5)	69 (46.6)	68 (46.3)		27 (47.4)	19 (33.3)	20 (35.7)	
2	64 (43.2)	52 (35.1)	49 (33.3)		20 (35.1)	24 (42.1)	22 (39.3)	
3	33 (22.3)	27 (18.2)	30 (20.4)		10 (17.5)	14 (24.6)	14 (25.0)	
<b>Hepatocyte ballooning</b>				<b>0.048</b>				0.398
0	15 (10.1)	21 (14.2)	25 (17.0)		10 (17.5)	7 (12.3)	4 (7.1)	
1	82 (55.4)	85 (57.4)	88 (59.9)		21 (36.8)	22 (38.6)	35 (62.5)	
2	51 (34.5)	42 (28.4)	34 (23.1)		26 (45.6)	28 (49.1)	17 (30.4)	
<b>Lobular inflammation</b>				<b>0.003</b>				0.900
0	9 (6.1)	25 (16.9)	18 (12.2)		4 (7.0)	7 (12.3)	5 (8.9)	
1	83 (56.1)	88 (59.5)	84 (57.1)		36 (63.2)	29 (50.9)	30 (53.6)	
2	52 (35.1)	33 (22.3)	42 (28.6)		15 (26.3)	21 (36.8)	21 (37.5)	
3	4 (2.7)	2 (1.4)	3 (2.0)		2 (3.5)	0	0	
<b>Fibrosis</b>				<b>&lt;0.001</b>				0.110
0	58 (39.2)	64 (43.2)	75 (51.0)		18 (31.6)	24 (42.1)	23 (41.1)	
1	54 (36.5)	65 (43.9)	52 (35.4)		14 (24.6)	17 (29.8)	21 (37.5)	
2	31 (20.9)	15 (10.1)	18 (12.2)		20 (35.1)	11 (19.3)	10 (17.9)	
3	4 (2.7)	4 (2.7)	2 (1.4)		2 (3.5)	5 (8.8)	1 (1.8)	
4	1 (0.7)	0	0		3 (5.3)	0	1 (1.8)	
<b>NASH</b>	75 (50.7%)	46 (31.1%)	55 (37.4)	<b>0.002</b>	21 (36.8%)	28 (49.1%)	32 (57.1%)	0.095

NASH with presence of fibrosis 69 (46.4%) 36 (24.3%) 43 (29.3%) <0.001 18 (31.5%) 26 (45.6%) 27 (48.2%) 0.124

---

*Abbreviations:* BP: blood pressure; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyltransferase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SVR: appendicular skeletal muscle mass to visceral fat area ratio; NASH: nonalcoholic steatohepatitis

\*P value < 0.05, vs. T1 in men, §P value < 0.05, vs. T1 in women.